dc.contributor.author
Schneider, Udo
dc.contributor.author
Siegert, Elise
dc.contributor.author
Gläser, Sven
dc.contributor.author
Krüger, Klaus
dc.contributor.author
Krause, Andreas
dc.contributor.author
Die Kommission Pharmakotherapie der DGRh
dc.date.accessioned
2023-08-18T10:56:38Z
dc.date.available
2023-08-18T10:56:38Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40526
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40246
dc.description.abstract
Interstitial lung disease in systemic sclerosis (SSc-ILD) is a frequent organ complication with considerable mortality. Therapeutically, immunosuppressants are primarily used, particularly cyclophosphamide (CYC) and mycophenolate mofetil (MMF). Recently acquired data also showed an efficacy of the biologics rituximab and tocilizumab. The therapeutic options have most recently been expanded by the approval of the antifibrotic drug nintedanib. It is particularly beneficial in progressive fibrosing courses of ILD despite immunosuppression. The data from controlled trials on the efficacy and safety of CYC and MMF compiled in this review argue for a preferential use of MMF; however, the approval of MMF for this indication is still lacking. This is urgently needed for improved and simplified care of patients with SSc-ILD.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Immunosuppression
en
dc.subject
Cyclophosphamide
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Stellenwert von Mycophenolat-Mofetil zur Behandlung der interstitiellen Lungenerkrankung bei systemischer Sklerose
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00393-021-01088-y
dcterms.bibliographicCitation.journaltitle
Zeitschrift für Rheumatologie
dcterms.bibliographicCitation.number
9
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
868
dcterms.bibliographicCitation.pageend
878
dcterms.bibliographicCitation.volume
80
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34545432
dcterms.isPartOf.issn
0340-1855
dcterms.isPartOf.eissn
1435-1250